ea0037ep1132 | Endocrine tumours | ECE2015
Modica Roberta
, Ramundo Valeria
, Marciello Francesca
, Marotta Vincenzo
, Pizza Genoveffa
, Carratu Anna Chiara
, Roseto Chiara de Luca di
, Buonomano Pasqualina
, Giordano Carla
, Trimarchi Francesco
, Colao Annamaria
, Faggiano Antongiulio
Somatostatin analogs (SSA) effectively control symptoms in neuroendocrine tumours (NET), besides showing antiproliferative activity. In progressive or metastatic NET, increasing SSA dose or shortening the dosing interval are common clinical practice, though empirical. Aim of this study is to evaluate efficacy and safety of high-dose SSA treatment in patients with progressive disease under standard SSA dose. Twenty-one patients (median age 56.8 years) with NET of different orig...